Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
Rocket PharmaceuticalsRocket Pharmaceuticals(US:RCKT) Seeking Alpha·2026-03-28 02:45

公司产品与监管进展 - 公司召开投资者电话会议，讨论其基因疗法产品KRESLADI (RP-L201)获得美国食品药品监督管理局批准[1] - 获批产品KRESLADI (RP-L201)是一种基于慢病毒载体的基因疗法[1] - 该疗法获批用于治疗严重白细胞粘附缺陷症I型患者[1]

Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript - Reportify